# Lilly's obesity pill maintains weight lost on injectable GLP-1s - Fierce Biotech

## Metadata
| Field | Value |
|-------|-------|
| Source | Fierce Biotech |
| URL | https://news.google.com/rss/articles/CBMixAFBVV95cUxNU1pHNG9TTmpNbmd0ZnJaS05aeHBKNDNuS3JycXExQ1E2NWpVRmthQkt6Slk0dGYyWW50eGR5bWpqbmNBamJmYlBlclJWaGN3dnZvWHljRXdXZnBObUFkSWxlcFREUWpIcFgtUHo3aUF6Vzhhc1ExdjMyU254OFl6RVFQTEpIc2ZWZUwzdFlad0ZZQnJaZ2t6WERSUVE5MUhUenZ0NHo1X0YwUU42UFM1ZFljVFY5VUNkY1Q0RDBmREdtdWZy?oc=5&hl=en-US&gl=US&ceid=US:en |
| Scraped | 2025-12-29 18:01 |
| Category | GLP-1 |
| Relevance | 9/10 |
| Signal | bull |

## Investment Summary
Eli Lilly demonstrates continued efficacy of oral obesity treatment, potentially disrupting current injectable GLP-1 market and signaling ongoing innovation in weight management therapeutics.

## Key Entities
Eli Lilly, Novo Nordisk

## Dollar Amounts
None mentioned

---

## Article Content

*Full content could not be extracted. Visit URL for details.*

---

#healthcare-news #glp-1 #auto-scraped
